PRNewsWire
03 Jun 2026, 04:03 UTC · 3h ago
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Search tags
PRNewsWire
03 Jun 2026, 04:03 UTC · 3h ago
Search tags
Story key points
3 claims · impact-rated
Johnson & Johnson reported that nipocalimab achieved a 62.5% response rate in the autoantibody-high subgroup compared to 51.9% in the overall Phase 2 DAHLIAS population. — Stronger-than-average efficacy in a high-burden subgroup increases the probability of success for the ongoing Phase 3 trial.
+0.60Nipocalimab is currently being evaluated in the Phase 3 DAFFODIL study for the management of systemic Sjögren's disease. — Progression to Phase 3 indicates a high-value pipeline asset moving closer to potential commercialization and FDA approval.
+0.30New biomarker analyses suggest nipocalimab's mechanism of action effectively reduces pathogenic IgG autoantibodies while preserving broader immune function. — Validation of the drug's biological mechanism reduces clinical risk and supports the targeted nature of the therapy.
+0.20Ticker attribution
Continue reading
6 related stories
Model heads
The company announced positive Phase 2 biomarker data for nipocalimab in treating Sjögren's disease, supporting its continued development.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
3h ago
